The present invention relates to herbal medicine extracts useful in the prevention or treatment of diseases caused by influenza viruses, and to a pharmaceutical composition or health food comprising the extracts. The herbal medicine extracts of the present invention are derived from natural materials, and are safe for the human body, and can be used in preventing and treating and in relieving symptoms of diseases caused by various types of influenza viruses.
|
1. A method for treating influenza virus in a human in need thereof consisting essentially of administering a therapeutically effective amount of a Epimedium koreanum extract to said human to treat said influenza virus.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a U.S. National Stage Application under 35 U.S.C. §371 of International Patent Application No. PCT/KR2010/007522, filed 29 Oct. 2010, which claims the benefit of priority to South Korean Patent Application No. 10-2009-0106113, filed 4 Nov. 2009, the disclosures of all of which are hereby incorporated by reference in their entireties. The International Application was published in Korean on 12 May 2011 as WO 2011/055931. To the extent appropriate, a claim of priority is made to each of the above disclosed applications.
The present invention relates to a herbal extract useful for the prevention and/or treatment of influenza virus-induced diseases, more precisely, to a herbal extract that is very effective in preventing and/or treating influenza virus-induced diseases, particularly those infecting human.
Influenza virus is a RNA virus belonging to Family Orthomyxoviridae which causes inflammation in respiratory system. This is a highly infectious virus that infects others via direct communication through air from cough or saliva of the infected ones or via indirect communication through anything that is touched by the infected ones. The incubation period of this virus is 24˜30 hours and serotype of the virus is divided as type A, type B, and type C. Type B and type C are confirmed to infect only human, while type A can infect not only human but also various species of mammals including horse, pig, and others, and also various species of domestic poultry and wild birds (Selmons et al., Avian Dis., 18(1), p. 119-124, 1974; Webster R G et al., Microbiol Rev., 56(1), p. 152-179, 1992).
The classification of serotype of type A influenza virus depends on the two kinds of proteins observed on the surface of the virus, which are Hemagglutinin (HA) and Neuraminidase (NA). Type A virus can be divided into 144 different serotypes (16 kinds of HA and 9 kinds of NA). HA aids the virus to be attached on somatic cells, while NA helps the virus to invade into the cells (Alexander D J, Vet. Microbiol., 74(1-2), p. 3-13, 2000). The natural normal host for type A influenza virus is wild water birds such as duck and seagull. From the epidemiological studies of influenza virus infection in wild birds over the world, it was confirmed that all the existing 16 kinds of HA and 9 kinds of NA were found in wild birds (Selmons et al., Avian Dis., 18(1), p. 119-124, 1974). Avian influenza virus classified as type A is the zoonosis virus which is divided into three major groups (Alexander D J, Vet. Microbiol., 74(1-2), p. 3-13, 2000); which are non-pathogenic avian influenza that causes light respiratory symptoms when it infects chickens, low pathogenic avian influenza (LPAI) that causes 1˜30% mortality and egg drop syndrome, and highly pathogenic avian influenza (HPAI) called “Bird Flu” that shows high lethality of at least 95%. Particularly, HPAI is classified as List A disease by OIE (Office International des Epizooties) and as 1st class contagious animal disease in Korea.
Since 1980s, HPAI has been reported world-widely including USA (1983), Australia (1985, 1992, 1994 and 1997), Mexico (1994), Pakistan (1994 and 2004), Hong Kong (1997 and 2001), Italia (1997 and 1999), Netherland (2003), Belgium (2003), Germany (2003), and Canada (2004). In addition, starting with Korea (December, 2003), almost all the East-South Asian and Far East Asian countries including Vietnam, Japan, Thailand, Cambodia, Laos, Indonesia, and China reported the break-out of serotype A/H5N1 HPAI all at the same time in 2004. In particular, HPAI broken out in Vietnam and Thailand, unlike typical HPAI broken out in Korea and Japan at that time that has been characterized as not being infectious to human, was confirmed as a mutant avian influenza (mutant A/H5N1 HPAI) that was infectious to human via contact with infected birds. As of March, 2004 in Vietnam, 15 out of 22 people infected with the mutant form by the contact with the infected birds were dead and 8 out of 11 people were also killed in Thailand as well, worrying all the countries. The frequency of HPAI outbreak is 10 times higher than before. Since 2001, HPAI outbreak has been reported every year world-widely. Therefore, it is required to develop a novel prevention method which is effective in controlling HPAI (Song C S et al., Korean J. Poult. Sci., 31(2), p. 129-136, 2004).
Some serotypes of influenza virus, which causes problems in birds, cause even death in human after developing flu symptoms. Some mutant forms originated from three serotypes of avian influenza virus such as A/H7N7, A/H9N2, and A/H5N1 so called “Hong Kong avian influenza” are assumed to be infectious to human. Therefore, studies on such mutant virus forms originated from the above three serotypes have been eagerly going on word-widely (Suarez D L et al., J. Virol., 72(8), p. 6678-6688, 1998).
In the meantime, novel influenza that has been now prevailing all over the world since it was first found in Mexico in spring of 2009 is influenza type A subtype H1N1 having type 1 hemagglutinin (H1) and type 1 neuraminidase (N1) (Hereinafter, the said novel influenza A virus is called ‘2009 NIH1 influenza virus’). The 2009 NIH1 influenza virus is a kind of virus in which genetic materials of influenza viruses originated from human, swine, and birds are mixed. At this time swine is called as “mixing vessel”. Thus, it was first named as swine influenza. However, since there was no proof saying that this virus is directly delivered to human from infected swine or delivered to swine from infected human or related to swine whatsoever, WHO used to call it novel influenza A (H1N1). From the sequence analysis of 2009 N1H1 influenza virus, it was confirmed that HA gene includes a certain sequence that is infectious to human, suggesting the possibility of infecting human. HA gene does not contain dibasic amino acid, the typical amino acid of highly pathogenic virus, but comprises drug resistant gene against amantadine and rimantadine. The virus was also confirmed not to have any mutation in NS1 and PB2 genes in relation to pathogenicity, suggesting that the virus was not highly pathogenic. 2009 NIH1 influenza virus is infectious through respiratory system and is highly contagious compared with the conventional influenza A virus. The symptoms of this virus are similar to those of the conventional influenza virus, for example high fever, cough, etc. To prevent the infection, personal hygiene including hand-washing and wearing a mask is required. It is recommended to treat the virus infection to use antiviral agents such as Tamiflu and Relenza.
Once infected with influenza virus, each organ in respiratory system loses its resistance, resulting in the development of complications such as bronchitis, laryngopharyngitis, and pneumonia. Particularly, chronic disease patients, aged people, children, and long-term hospitalized patients are in high risk since their immunities are very weak. Therefore, studies to prevent influenza are going on in the aspects of biosecutity and influenza vaccine. However, to get vaccine shot, proper timing is important as well as the prediction of the kind of prevailing influenza virus, which are troublesome.
Efforts have been made world-widely to develop an antiviral agent. Up to date, lamibudine used for the treatment of HIV-1 and hepatitis B, gancyclovir used for the treatment of herpes virus infection, and ribavirin used for the treatment of respiratory syncytial virus infection and also used for the urgent care of diverse virus infections have been approved and now are on the market. In addition, amantadine approved for the treatment of influenza virus A and its analogue rimantadine, zanamivir (Relenza) artificially synthesized as an influenza virus neuraminidase inhibitor, and oseltamivir (TAMIFLU™) are also on the market. Amantadine and rimantadine are designed to inhibit the functions of M2 ion channel protein of influenza virus, which are representative antiviral agents suppressing in vivo proliferation of influenza virus. These two antiviral agents are only effective for serotype A influenza virus and not effective at all for serotype B influenza virus that does not contain M2 protein. There is another problem in using amantadine and rimantadine. That is, with the use of those drugs, a mutant virus is easily generated whose M2 ion channel protein is not affected by those drugs. Zanamivir and oseltamivir, developed to overcome the above problem, are designed to inhibit the functions of neuraminidase, which became representative antiviral agents inhibiting the proliferation of influenza virus in vivo. These two antiviral agents are known to be effective in inhibiting all of 16 kinds of serotype A influenza virus and all of serotype B influenza virus. However, zanamivir needs to be inhaled or injected intravenously, which is not an easy pathway. In the meantime, oseltamivir can be orally administered, but according to the recent reports, side effects such as vomiting and dizziness are accompanied with the oral administration and resistant virus has been also generated (Ward P et al., J. Antimicrob. Chemother., 55(suppl), p. i5-i21, 2005). Therefore, it is important to develop a safe natural agent along with the vaccine and therapeutic agents to increase human immunity and to reduce death rate upon pandemic of such virus.
To treat influenza in Oriental Medicine, different kinds of medicinal herbs are boiled together and the extract therefrom is used, which is exemplified by Insampaedoksan, Gumiganghwalsan, Galgeun-tang, Mahwang-tang, Daecheongryong-tang, Seungmagalgeun-tang, Chungjogupae-tang, Yihyangsan, and Baekhogainsam-tang. Many kinds of medicinal herbs are used, and these are more to increase immunity of human body than to act as an antiviral agent. Thus, it is urgent request to develop a novel drug to prevent and/or treat influenza virus-induced disease more fundamentally.
Thus, the present inventors investigated the effect of medicinal herbs used in Oriental Medicine on the activity of influenza virus. As a result, the present inventors confirmed that the herbal extract containing Epimedium koreanum had excellent preventive and/or therapeutic effect on diseases caused by various types of influenza viruses, leading to the completion of this invention.
It is an object of the present invention to provide a herbal extract containing Epimedium koreanum, and a composition and health food for the prevention or treatment of influenza virus-induced diseases comprising the said herbal extract as an active ingredient.
To achieve the above object, the present invention provides a herbal extract extracted from herb mixture containing Epimedium koreanum by using water or an organic solvent.
To prepare the herbal extract of the present invention, water or an organic solvent, preferably water, was added to herb mixture containing Epimedium koreanum by 2˜10 times the volume of the herb mixture, followed by extraction at 70˜100° C. for 1˜10 hours or preferably 3˜4 hours. However, the extraction is not limited to the above hot water extraction, and enfleurage, reflux extraction, or ultrasonic extraction can also be used. In addition to Epimedium koreanum, herbs used for the extraction is not limited and any medicinal herb generally used for the purpose of preventing or treating cold or flu in Oriental Medicine can be added without limitation. In this invention, the said organic solvent is exemplified by water, C1-C4 alcohol, C1-C4 ketone, C1-C4 aldehyde and aqueous solution of alcohol, ketone or aldehyde. Among these, water is more preferred.
In this invention, the said influenza virus preferably has the serotype selected from the group consisting of H1N1, H1N2, H2N2, Human B, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N2, and H10N7, and more preferably has the serotype selected from the group consisting of H1N1, H3N2, Human B, H5N1, H9N2, H7N1, and H7N2, and most preferably has the serotype of H1N1.
The herbal extract of the present invention can be administered orally or parenterally and be used in general forms of pharmaceutical formulation. That is, the herbal extract of the present invention can be prepared for oral or parenteral administration by mixing with generally used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants. Solid formulations for oral administration are tablets, pills, powders, granules and capsules. These solid formulations are prepared by mixing the said herbal extract with one or more suitable excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. Except for the simple excipients, lubricants, for example magnesium stearate, talc, etc, can be used. Liquid formulations for oral administrations are suspensions, solutions, emulsions and syrups, and the above-mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally used simple diluents such as water and liquid paraffin. Formulations for parenteral administration are sterilized aqueous solutions, water-insoluble excipients, suspensions, emulsions, lyophilized preparations and suppositories. Water insoluble excipients and suspensions can contain propylene glycol, polyethylene glycol, vegetable oil like olive oil, injectable ester like ethylolate, etc. Suppositories can contain witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, etc.
The herbal extract of the present invention can be administered to mammals such as human, cattle, swine, horses, sheep, rats, and mice, and birds such as fowls and ducks by various pathways. For example, the possible administration pathway can be oral administration, rectal administration, intravenous injection, intramuscular injection, hypodermic injection, intrauterine injection or intracerebroventricular injection. The effective dosage of the herbal extract of the present invention can be determined according to absorption of an active ingredient, inactivation rate, excretion, age, gender, health condition, and severity of a disease. In general, the dosage for adult is 10˜300 mg/kg per day and preferably 20˜100 mg/kg per day, and administration frequency is preferably 1˜6 times a day. The dosage unit can contain, for example, 1, 2, 3 or 4 individual doses or ½, ⅓ or ¼ of an individual dose. An individual dose preferably contains the amount of active compound which is administered in one application and which usually corresponds to a whole, ½, ⅓ or ¼ of a daily dose.
Since the herbal extract of the present invention is a natural substance and has no toxicity, it can be continuously administered at a high dose. The herbal extract of the present invention is evaluated to be a safe substance since its estimated LD50 value is much greater than 5 g/kg in mice, which is confirmed by toxicity assay with mice tested via oral administration.
In a preferred embodiment of the present invention, the herbal extract of the present invention does not show cytotoxicity at a comparatively high concentration, compared with Tamiflu used as the positive control (see Table 1), but demonstrated antiviral activity against diverse serotypes of influenza virus (see
The present invention also provides a health food for the prevention of influenza virus-induced disease or alleviation of its symptoms comprising the said herbal extract as an active ingredient. The health food herein indicates the food with improved functionality, compared with the general food, obtained by adding the herbal extract of the present invention thereto. The functionality herein indicates physical properties and physiological functions. When the herbal extract of the present invention is added to general food, physical properties and physiological functions of the food can be improved and such food improved in functions is described as ‘health food’ inclusively in this invention.
In this invention, the said influenza virus preferably has the serotype selected from the group consisting of H1N1, H1N2, H2N2, Human B, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H9N2, and H10N7, and more preferably has the serotype selected from the group consisting of H1N1, H3N2, Human B, H5N1, H9N2, H7N1, and H7N2, and most preferably has the serotype of H1N1.
The herbal extract of the present invention can be added to health food for the prevention of influenza virus induced disease or alleviation of its symptoms. In that case, the herbal extract of the present invention can be added as it is or as mixed with other food components according to the conventional method. The mixing ratio of active ingredients can be regulated according to the purpose of use (prevention, health enhancement or treatment). In general, to produce health food or beverages, the herbal extract of the present invention is added preferably by up to 30 wt % and more preferably by up to 10 wt %. However, if long term administration is required for health and hygiene or regulating health condition, the content can be lower than the above but higher content can be accepted as well since the herbal extract of the present invention has been proved to be very safe.
The food herein is not limited. For example, the herbal extract of the present invention can be added to meats, sausages, breads, chocolates, candies, snacks, cookies, pizza, ramyuns, flour products, gums, dairy products including ice cream, soups, beverages, tea, drinks, alcohol drinks and vitamin complex, etc, and in wide sense, almost every food applicable in the production of health food can be included.
The composition for health beverages of the present invention can additionally include various flavors or natural carbohydrates, etc, like other beverages. The natural carbohydrates above can be one of monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and glucose alcohols such as xilytole, sorbitol and erythritol. Besides, natural sweetening agents such as thaumatin and stevia extract, and synthetic sweetening agents such as saccharin and aspartame can be included as a sweetening agent. The content of the natural carbohydrate is preferably 0.01˜0.04 g and more preferably 0.02˜0.03 g in 100 ml of the herbal extract of the present invention.
In addition to the ingredients mentioned above, the herbal extract of the present invention can include in a variety of nutrients, vitamins, minerals, flavors, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acid, protective colloidal viscosifiers, pH regulators, stabilizers, antiseptics, glycerin, alcohols, carbonators which used to be added to soda, etc. The herbal extract of the present invention can also include natural fruit juice, fruit beverages and/or fruit flesh addable to vegetable beverages. All the mentioned ingredients can be added singly or together. The mixing ratio of those ingredients does not matter in fact, but in general, each can be added by 0.016˜0.1 weight part per 100 weight part of the herbal extract of the present invention.
The herbal extract of the present invention comprising Epimedium koreanum is very safe for human body because it is originated from the natural source, so that it can be used for the prevention and treatment of various influenza virus-induced diseases and alleviation of symptoms of those.
The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:
Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
Homegrown Epimedium koreanum was purchased and used as the test sample. One l of water was added to approximately 55 g of the selected Epimedium koreanum, which stood at room temperature for 1 hour. Then hot water extraction was performed at 100° C. for 3 hours, and as a result, approximately 100 ml of Epimedium koreanum extract was obtained. Approximately 4.7 g of freeze-dried material was obtained by freeze-drying the obtained Epimedium koreanum extract. The Epimedium koreanum extract or its freeze-dried material was used in this invention.
MDCK cells were distributed in a 96-well plate at the density of 1.5×105 cells/ml. Screening was performed when confluence reached 70-80%. The cells were washed with 1×PBS twice. The Epimedium koreanum extract prepared in Example 1 was diluted at different concentrations of 3.7, 1.23, 0.41, 0.14, and 0.05 mg/ml, which was added to each well containing 100 μl of cell growth medium (MEM+10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin). The cells were cultured in a 5% CO2 incubator at 37° C. for 48 hours. Then, MTT assay was performed to investigate cytotoxicity. For the positive control, Tamiflu was used at the concentrations of 1.23, 0.41, and 0.14 mg/ml.
As a result, the Epimedium koreanum extract showed cytotoxicity at the high concentration of 3.7 mg/ml, but did not show cytotoxicity at the concentration under 1.23 mg/ml. In the meantime, Tamiflu used as the positive control showed high cytotoxicity at the concentration of 1.23 mg/ml, and also demonstrated comparatively high cytotoxicity at the concentrations of 0.41 and 0.14 mg/ml as well, compared with the Epimedium koreanum extract (Table 1). Therefore, antiviral activity against influenza virus of the extract of the present invention was compared with that of the control at the concentrations of 1.23 mg/ml, 0.41 mg/ml, and 0.14 mg/ml, respectively.
TABLE 1
Cell viability (%)
Concentration of
3.7
1.23
0.41
0.14
0.05
treated sample
mg/ml
mg/ml
mg/ml
mg/ml
mg/ml
Virus growth
100
100
100
100
100
medium
(negative control)
Epimedium koreanum
75.4
78.2
89.9
94.7
96
extract
Positive control
—
20.83
54.94
64.02
—
MDCK cells were distributed in a 96-well plate at the density of 1.5×105 cells/ml. Screening was performed when confluence reached 70-80%. The cells were washed with 1×PBS twice. Virus growth medium (MEM+0.3% BSA, 2 μg N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) treated 1 μg/ml trypsin, 100 U/ml penicillin, and 0.1 mg/ml streptomycin) was added to each well, followed by culture in a 5% CO2 incubator at 37° C. for 15 minutes. The cells were inoculated with 100 TCID50 of each H1N1 and H5N1, and 10 TCID50 of H3N2, followed by culture in a 5% CO2 incubator at 37° C. for 2 hours. 100 μl of virus growth medium containing Epimedium koreanum extract at the concentration of 1.23 mg/ml, 0.41 mg/ml, or 0.14 mg/ml was added thereto, followed by culture in a 5% CO2 incubator at 37° C. for 48 hours. MTT assay was performed to investigate the antiviral activity of the Epimedium koreanum extract. For the positive control, Tamiflu was used at the concentrations of 1.23, 0.41, and 0.14 mg/d.
As a result, the Epimedium koreanum extract of the present invention demonstrated antiviral activity against PR8 H1N1 and H5N1 dose-dependently. The antiviral activity of the extract against Brisbane H1N1 was highest at comparatively low concentrations of 0.41 and 0.14 mg/ml. The extract also demonstrated antiviral activity against H3N2, and the activity at three different concentrations was all similar (
Six weeks old specific pathogen-free (SPF) SD rats, provided from Daehan Biolink, Co., Ltd., Korea, were used for the following acute toxicity test. The Epimedium koreanum extract of Example 1 was orally administered once to 2 rats per group at the concentrations of 5 g/kg. Death, clinical symptoms, and weight changes in rats were observed, hematological tests and biochemical tests of blood were performed, and any abnormal signs in the gastrointestinal organs of chest and abdomen were checked with eyes during autopsy.
The results showed that the extract did not cause any specific clinical symptoms, weight change, or death in rats. No change was observed in hematological tests, biochemical tests of blood, and autopsy. The extract of the present invention is evaluated to be a safe substance since it does not cause any toxic change in rats up to the level of 5 g/kg and its estimated LD50 value is much greater than 5 g/kg in rats.
<1-1> Preparation of Syrups
Syrups containing the herbal extract of the present invention by 2% (weight/volume) as an effective ingredient were prepared as follows. The herbal extract powder prepared in Example 1, saccharin, and sucrose were dissolved in 80 g of warm water. The mixture was cooled down, to which a mixture of glycerin, saccharin, flavors, ethanol, sorbic acid, and distilled water was added. Water was added to the mixture, making a total volume of 100 ml.
The constituents of the syrups are as follows.
Herbal extract
2 g
Saccharin
0.8 g
Sucrose
25.4 g
Glycerin
8.0 g
Flavor
0.04 g
Ethanol
4.0 g
Sorbic acid
0.4 g
Distilled water
Proper amount
<2-2> Preparation of Tablets
Tablets containing 15 mg of the herbal extract of the present invention as an active ingredient were prepared as follows.
250 g of the herbal extract prepared in Example 1, 175.9 g of lactose, 180 g of potato-starch, and 32 g of colloidal silicic acid were all mixed together. 10% gelatin solution was added to the mixture, which was then pulverized and filtered with 14-mesh sieve. The pulverized mixture was dried, to which 160 g of potato-starch, 50 g of talc, and 5 g of magnesium stearate were added to prepare tablets.
<1-3> Preparation of Injectable Solution
Injectable solutions containing 10 mg of the herbal extract of the present invention as an active ingredient were prepared as follows. 1 g of the herbal extract prepared in Example 1, 0.6 g of sodium chloride, and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml of solution. The solution was put in a bottle and heated at 20° C. for 30 minutes for sterilization.
<1-4> Preparation of Powders
Powders were prepared by mixing 20 mg of the herbal extract prepared in Example 1, 100 mg of lactose, and 10 mg of talc, which were filled in airtight packs according to the conventional method for preparing powders.
<1-5> Preparation of Capsules
Capsules were prepared by mixing 10 mg of the herbal extract prepared in Example 1, 3 mg of crystalline cellulose, 14.8 mg of lactose, and 0.2 mg of magnesium stearate, which were filled in gelatin capsules according to the conventional method for preparing capsules.
<2-1> Preparation of Food
Foods containing the herbal extract of the present invention were prepared as follows.
1. Preparation of Spices for Cooking
Health enhancing spices for cooking were prepared with 20˜95 wt % of the herbal extract of the present invention according to the conventional method.
2. Preparation of Tomato Ketchup and Sauce
Health enhancing tomato ketchup or sauce was prepared by mixing 0.2˜1.0 wt % of the herbal extract of the present invention with tomato ketchup or sauce according to the conventional method.
3. Preparation of Flour Foods
The herbal extract of the present invention was added to the flour by 0.5˜5.0 wt %. Health enhancing foods such as bread, cake, cookies, crackers and noodles were prepared with the flour mixture according to the conventional method.
4. Preparation of Soups and Gravies
The herbal extract of the present invention was added to soups and gravies by 0.1˜5.0 wt %. Health enhancing meat products, soups and gravies were prepared with this mixture by the conventional method.
5. Preparation of Ground Beef
Health enhancing ground beef was prepared by mixing 10 wt % of herbal extract of the present invention with ground beef according to the conventional method.
6. Preparation of Dairy Products
The herbal extract of the present invention was added to milk by 5˜10 wt %. Health enhancing dairy products such as butter and ice cream were prepared with the milk mixture according to the conventional method.
7. Preparation of Sun-Sik
Brown rice, barley, glutinous rice, and Yulmu (Job's tears) were gelatinized according to the conventional method, dried and pulverized to obtain 60-mesh powders. Black soybean, black sesame and wild sesame were steamed and dried according to the conventional method and pulverized to obtain 60-mesh powders. The herbal extract of the present invention was concentrated under reduced pressure, spray-dried and pulverized to obtain 60-mesh dry powders. Sun-Sik was prepared by mixing the dry powders of the grains, seeds and the herbal extract of the present invention according to the below ratio.
Grains (brown rice: 30 wt %, Yulmu: 15 wt %, barley: 20 wt %),
Seeds (wild sesame: 7 wt %, black soybean: 8 wt %, black sesame: 7 wt %),
Dry powders of the herbal extract (3 wt %),
Ganoderma lucidum (0.5 wt %),
Rehmannia glutinosa (0.5 wt %)
<2-2> Preparation of Beverages
1. Preparation of Carbonated Beverages
Syrup was prepared by mixing the herbal extract of the present invention with sugar (5-10%), citric acid (0.05-0.3%), caramel (0.005-0.02%), vitamin C (0.1-1%), and purified water (79-94%). The syrup was sterilized at 85-98° C. for 20-180 seconds, and then mixed with cooling water at the ratio of 1:4. Carbon dioxide was injected thereto by 0.5-0.82% to prepare carbonated beverages containing the herbal extract of the present invention.
2. Preparation of Health Beverages
The herbal extract of the present invention was mixed with liquid fructose (0.5 wt %), oligosaccharide (2 wt %), sugar (2 wt %), salt (0.5 wt %), and water (75 wt %). After mixing completely, the mixture was sterilized instantly and filled small containers such as glass bottles, pet bottles, etc, to prepare health beverages.
3. Preparation of Vegetable Juice
Health enhancing vegetable juice was prepared by adding 5 g of the herbal extract of the present invention to 1,000 ml of tomato or carrot juice according to the conventional method.
4. Preparation of Fruit Juice
Health enhancing fruit juice was prepared by adding 1 g of the herbal extract of the present invention to 1,000 ml of apple or grape juice according to the conventional method.
Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
Lee, Jae Hoon, Ma, Jin Yeul, Um, Young Ran, Park, Hwa Yong
| Patent | Priority | Assignee | Title |
| 10149822, | Feb 11 2015 | Johnson & Wales University | Compositions and methods for combination ingredient delivery |
| 9498435, | Feb 11 2015 | Johnson & Wales University | Compositions and methods for combination ingredient delivery |
| Patent | Priority | Assignee | Title |
| 20020064542, | |||
| EP568001, | |||
| JP2009046391, | |||
| KR100142655, | |||
| KR1019950014593, | |||
| KR1020050116199, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 29 2010 | Korea Institute of Oriental Medicine | (assignment on the face of the patent) | / | |||
| Jul 09 2012 | MA, JIN YEUL | Korea Institute of Oriental Medicine | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028567 | /0588 | |
| Jul 09 2012 | UM, YOUNG RAN | Korea Institute of Oriental Medicine | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028567 | /0588 | |
| Jul 09 2012 | LEE, JAE HOON | Korea Institute of Oriental Medicine | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028567 | /0588 | |
| Jul 09 2012 | PARK, HWA YONG | Korea Institute of Oriental Medicine | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028567 | /0588 |
| Date | Maintenance Fee Events |
| Jan 19 2017 | ASPN: Payor Number Assigned. |
| Jun 30 2017 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Aug 30 2021 | REM: Maintenance Fee Reminder Mailed. |
| Feb 14 2022 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jan 07 2017 | 4 years fee payment window open |
| Jul 07 2017 | 6 months grace period start (w surcharge) |
| Jan 07 2018 | patent expiry (for year 4) |
| Jan 07 2020 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 07 2021 | 8 years fee payment window open |
| Jul 07 2021 | 6 months grace period start (w surcharge) |
| Jan 07 2022 | patent expiry (for year 8) |
| Jan 07 2024 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 07 2025 | 12 years fee payment window open |
| Jul 07 2025 | 6 months grace period start (w surcharge) |
| Jan 07 2026 | patent expiry (for year 12) |
| Jan 07 2028 | 2 years to revive unintentionally abandoned end. (for year 12) |